Holen Sie sich die Stockscreener-App
4.135
3.89%
0.155
Handel nachbörslich:
4.18
0.045
+1.09%
Candel Therapeutics Inc Aktie (CADL) Neueste Nachrichten
HC Wainwright Issues Pessimistic Estimate for CADL Earnings - MarketBeat
Analysts Issue Forecasts for CADL Q4 Earnings - Defense World
HC Wainwright Reaffirms Buy Rating for Candel Therapeutics (NASDAQ:CADL) - Defense World
What is HC Wainwright's Forecast for CADL Q4 Earnings? - MarketBeat
Candel Therapeutics Advances in Cancer Trials Amid Financial Challenges - TipRanks
HC Wainwright Reaffirms "Buy" Rating for Candel Therapeutics (NASDAQ:CADL) - MarketBeat
Candel Therapeutics, Inc. (NASDAQ:CADL) Short Interest Update - MarketBeat
Candel Therapeutics Inc (CADL) Quarterly 10-Q Report - Quartzy
Candel Therapeutics CEO anticipates 'paradigm shift' in prostate cancer treatment as Q3 work wraps up - Proactive financial news
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - The Manila Times
Candel Therapeutics Reports $10.6M Q3 Loss, Advances Key Cancer Drug Trials for Q4 2024 | CADL Stock News - StockTitan
Insiders Could Have Profited By Holding onto Candel Therapeutics Shares Despite 10% Drop - Simply Wall St
Candel Therapeutics’ CAN-3110 offers new hope for melanoma treatment – ICYMI - Proactive Investors USA
CADLCandel Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Candel Therapeutics CEO to present at Jefferies London healthcare conference - Proactive Investors UK
Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024 - GlobeNewswire
Candel Therapeutics (NASDAQ:CADL) Shares Up 2.5%Should You Buy? - MarketBeat
Candel Therapeutics presents preclinical data with CAN-3110 in Melanoma model at SITC annual Meeting - Proactive Investors USA
Candel Therapeutics to Present Preclinical Data at SITC - GlobeNewswire
Candel Therapeutics eyes new indication for CAN-3110 in melanoma following positive preclinical results - Proactive Investors UK
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma - StockTitan
Nfi Group Inc. (NFI-T) QuotePress Release - The Globe and Mail
Candel Therapeutics: A Low-Price Oncolytic Virus Play Further Along Than You Think - Seeking Alpha
Candel Therapeutics Advances in Cancer Treatment Trials - Yahoo Finance
Candel Therapeutics Showcases Innovative Cancer Therapy - GlobeNewswire
Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC) - StockTitan
Candel Therapeutics Prices IPO At $8/Share - RTTNews
Where are the Opportunities in (CADL) - Stock Traders Daily
Candel Therapeutics Poised for Breakthrough in Cancer Therapies, Key Trials to Read Out by Year-End - Proactive Investors Australia
Candel Therapeutics Share PriceCADL, RNS News, Articles, Quotes, & Charts (NASDAQ:CADL) - Proactive Investors USA
(CADL) Trading Advice - Stock Traders Daily
Candel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Estuardo Aguilar-Cordova Sells 15,000 Shares - MarketBeat
Candel therapeutics investor sells $243,834 in stock By Investing.com - Investing.com South Africa
Banxa Holdings Inc (BNXAF) QuotePress Release - The Globe and Mail
How To Trade (CADL) - Stock Traders Daily
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting - The Manila Times
Candel Therapeutics to Present Preclinical Data on - GlobeNewswire
Candel therapeutics insider sells shares worth over $240k By Investing.com - Investing.com South Africa
Candel therapeutics insider sells shares worth over $240k - Investing.com India
Candel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Estuardo Aguilar-Cordova Sells 1,800 Shares - MarketBeat
Citigroup Raises Cogent Biosciences (NASDAQ:COGT) Price Target to $15.00 - Defense World
Citi raises Cogent price target on bezuclastinib potential - Investing.com India
Deeper Dive: Understanding Cg Oncology Inc. (CGON) Through its Various Ratios - The Dwinnex
(CADL) Proactive Strategies - Stock Traders Daily
Gaining Ground: Cogent Biosciences Inc (COGT) Closes Lower at 10.65, Down -3.01 - The Dwinnex
Cg Oncology Inc. [CGON] Stock sold by Insider Song Hong Fang for $23.0 million - Knox Daily
Capricor Therapeutics Shares Rise in Premarket on Plans to File Application for Deramiocel - MarketWatch
Cintas Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Benzinga
Farallon Capital Management LLC Decreases Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Kayne Anderson Rudnick Investment Management LLC Trims Holdings in Copart, Inc. (NASDAQ:CPRT) - Defense World
Circassia Pharmaceuticals Announces Strong H1 2024 Results - TipRanks
Cadence Design Systems Inc. stock rises Monday, still underperforms market - MarketWatch
Xponance Inc. Has $24.15 Million Holdings in Cadence Design Systems, Inc. (NASDAQ:CDNS) - Defense World
Hood River Capital Management LLC Has $13.71 Million Holdings in Cadence Design Systems, Inc. (NASDAQ:CDNS) - Defense World
Mizuho recommends buying Corbus following its drop post-Novo's obesity data (NASDAQ:CRBP) - Seeking Alpha
Is it possible to buy Candel Therapeutics Inc(CADL) shares at a good price now? - US Post News
0.93%
3.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):